Our findings demonstrate the role of the FUBP3 gene located on der (9) in poor response and progression in CML with the identification of additional druggable targets such as PAK1 in improving response outcomes in CML patients. The gene discussed is FUBP3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.